Armata Pharmaceuticals Inc is a late clinical-stage biotechnology company focused on the development of high-purity and potent, pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections using proprietary bacteriophage-based technology... Show more
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| LQDM | 23.25 | 0.20 | +0.87% |
| Amplify LQD Investment Grade 12% Target Income ETF (LQDM) | |||
| MDIV | 16.08 | 0.13 | +0.82% |
| Multi-Asset Diversified Income Index Fund (MDIV) | |||
| VTEI | 97.60 | 0.75 | +0.78% |
| Vanguard Intermediate-Term Tax-Exempt Bond ETF (VTEI) | |||
| GTOS | 24.60 | 0.02 | +0.08% |
| Invesco Short Duration Total Return Bond ETF (GTOS) | |||
| DECM | 34.37 | -0.06 | -0.19% |
| FT Vest U.S. Equity Max Buffer ETF - December (DECM) | |||
A.I.dvisor indicates that over the last year, ARMP has been loosely correlated with RANI. These tickers have moved in lockstep 44% of the time. This A.I.-generated data suggests there is some statistical probability that if ARMP jumps, then RANI could also see price increases.
| Ticker / NAME | Correlation To ARMP | 1D Price Change % | ||
|---|---|---|---|---|
| ARMP | 100% | +12.75% | ||
| RANI - ARMP | 44% Loosely correlated | -2.88% | ||
| NERV - ARMP | 43% Loosely correlated | +0.42% | ||
| DMRA - ARMP | 34% Loosely correlated | +0.84% | ||
| SION - ARMP | 32% Poorly correlated | -1.81% | ||
| ARTV - ARMP | 30% Poorly correlated | -4.47% | ||
More | ||||
a developer of novel bacteriophage-based therapeutics
Industry Biotechnology
The Moving Average Convergence Divergence (MACD) for ARMP turned positive on October 20, 2026. Looking at past instances where ARMP's MACD turned positive, the stock continued to rise in 44 of 47 cases over the following month. The odds of a continued upward trend are 90%.
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where ARMP's RSI Oscillator exited the oversold zone, 26 of 30 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 87%.
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 56 of 66 cases where ARMP's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 85%.
Following a +21.22% 3-day Advance, the price is estimated to grow further. Considering data from situations where ARMP advanced for three days, in 217 of 253 cases, the price rose further within the following month. The odds of a continued upward trend are 86%.
ARMP may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Momentum Indicator moved below the 0 level on October 09, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on ARMP as a result. In 93 of 107 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 87%.
The 10-day moving average for ARMP crossed bearishly below the 50-day moving average on September 21, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 18 of 20 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 90%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ARMP declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 87%.
The Aroon Indicator for ARMP entered a downward trend on October 22, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The Tickeron PE Growth Rating for this company is 13 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 59 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (-0.555) is normal, around the industry mean (2.973). P/E Ratio (-0.652) is within average values for comparable stocks, (-1.705). Projected Growth (PEG Ratio) (0.260) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (128.121) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (438.009).
The Tickeron Price Growth Rating for this company is 89 (best 1 - 100 worst), indicating slightly worse than average price growth. ARMP’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ARMP’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.